Call it a PrEP against heart disease
Official site: reprievetrial.org
A large, multi-site clinical trial dubbed REPRIEVE has begun enrolling across the U.S. and around the world to examine whether a medication called pitavastatin can prevent cardiovascular disease in people with HIV.
See full article by David Heitz here.
The REPRIEVE trial is looking to see if a statin medicine can reduce the risk of heart disease for people living with HIV. To join the trial, people must be living with HIV, be between the ages of 40 and 75 and must be on anti-HIV medicines (ART) for at least 6 months. We can discuss other requirements with you. You do not have to be a patient at University Hospitals to enroll in this study. Compensation is provided. For more information, please call us on our confidential line at 216-844-4444 or email us confidentially at email@example.com. Visit us on our website www.clevelandhiv.org.
Watch a short video about the REPRIEVE trial here: https://youtu.be/MNDKfsAkNDQ